Anti-TNF-α Agents in the Treatment of Crohn's Disease: A Systematic Review
Jinging LIAN,Lijia DING,Shiyao CHEN,Hongchun LIU
DOI: https://doi.org/10.3969/j.issn. 1008-7125.2009.10.006
2009-01-01
Abstract:Background: Up to now, there has been no effective treatment to cure Crohn's disease (CD), the advent of anti-tumor necrosis factor-α (TNF-α) agents has brought the patients a new option. Aims: To systematically evaluate the efficacy and safety of anti-TNF-α agents in the treatment of CD. Methods: Electronic database including MEDLINE/PubMed, OVID, Elsevier ScienceDirect, ISI Web of Knowledge, Cochrane Central Register of Controlled Trials, CBM, CNKI and VIP were retrieved. Besides, the references of articles retrieved and abstracts of some important conferences were also searched manually. Only randomized controlled trials (RCT) of anti-TNF-α agent therapy for CD were included. The quality of selected articles was assessed by Jadad scale and meta-analysis was conducted using RevMan 4.2 software. Results: Fifteen RCTs articles with high quality (Jadad score ≥3) were selected for this study. Compared with placebo, anti-TNF-α agents achieved significantly higher rates of clinical response (44.9% vs. 30.0%, RR=1.39, 95% CI: 1.16-1.67, P=0.0004) and clinical remission (29.3% vs. 18.7%, RR=1.63, 95% CI: 1.26-2.09, P=0.0001). The difference in fistula closure rate between these two groups was also significant (40.6% vs. 25.2%, RR=1.74, 95% CI: 1.23-2.45, P=0.002). Subgroup analysis showed that, both in induction therapy and maintenance therapy, the clinical response rate and remission rate in treatment group were higher than those in placebo group. Rates of adverse events were similar in treatment group and placebo group (77.0% vs. 75.5%, RR=1.01, 95% CI: 0.96-1.07, P=0.57), so as the rates of serious adverse events (11.6% vs. 12.6%, RR=0.87, 95% CI: 0.73-1.04, P=0.13). Conclusions: Anti-TNF-α agents are superior to placebo in the treatment of CD and have similar risks of adverse events and serious adverse events. Long-term trials with large samples are needed for the assessment of its safety and tolerance.